Genetics Research
rs11881222
Population Frequencies12
African
A 0.6761G 0.3239AA 0.456928AG/GA 0.43844GG 0.104632pop=9,844
African American
A 0.6745G 0.3255AA 0.454259AG/GA 0.440411GG 0.105329pop=9,532
African Others
A 0.728G 0.272AA 0.538462AG/GA 0.378205GG 0.083333pop=312
Asian
A 0.923G 0.077AA 0.849785AG/GA 0.145923GG 0.004292pop=466
East Asian
A 0.916G 0.084AA 0.837563AG/GA 0.15736GG 0.005076pop=394
European
A 0.701841G 0.298159AA 0.492957AG/GA 0.417768GG 0.089274pop=101,664
Latin American 1
A 0.6606G 0.3394AA 0.446244AG/GA 0.428756GG 0.125pop=3,088
Latin American 2
A 0.6265G 0.3735AA 0.391636AG/GA 0.469818GG 0.138545pop=5,500
Other
A 0.6897G 0.3103AA 0.477898AG/GA 0.423686GG 0.098415pop=4,796
Other Asian
A 0.96G 0.04AA 0.916667AG/GA 0.083333GG 0pop=72
South Asian
A 0.774G 0.226AA 0.573171AG/GA 0.402439GG 0.02439pop=164
Studies13
Unread Studies13 ▼
1
Pharmacogenomic (PGx) variants can significantly impact drug response, but limited data exists on their prevalence in Middle Eastern populations. This study aimed to investigate the inheritance of certain markers in candidate pharmacogenes among healthy Saudis. DNA samples from 95 unrelated healthy Saudi participants were genotyped using the Affymetrix Axiom Precision Medicine Diversity Array. Thirty-eight variants in 15 pharmacogenes were analyzed based on their clinical relevance and lack of p…
2
Although most hepatitis C virus (HCV)-infected individuals develop chronic infection, about 25% of them are able to clear the virus spontaneously without any therapeutic intervention. The aim of the present study was to identify genes associated with spontaneous HCV clearance in a population of Iranian patients. We genotyped 110 single-nucleotide polymorphisms (SNPs) in 59 selected--candidate--genes in a cohort of 107 HCV-infected participants who spontaneously cleared the infection and 176 part…
3
Hepatitis C virus (HCV) infection is associated with both viral and host factors. Cytokines, such as interferon (IFN)-λ, play a critical role in modulating the innate and adaptive immune systems. This study aims to investigate the association between single-nucleotide polymorphisms (SNPs) of interleukin (IL) 28B, IL10RB, and IL28RA genes and susceptibility to HCV infection in a population from the Liaoning Province of China. We used high resolution melt-polymerase chain reaction (HRM-PCR)…
4
This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.
5
Pegylated interferon combined with ribavirin treatment is an effective therapy for chronic hepatitis C viral infection. However, pegylated interferon combined with ribavirin is associated with various adverse reactions. Severe thrombocytopenia is a life-threatening side effect of interferon therapy that can lead to bleeding. It is generally understood that the inosine triphosphatase-CC genotype does not have a significantly lower reduction by pegylated interferon combined with ribavirin in the m…
6
Interleukin-28B (IL28B) polymorphisms have previously been reported to be strongly associated with spontaneous and treatment-induced HCV viral clearance. To assess the impact of four different IL28B polymorphisms and their haplotype combination and interferon-c inducible protein 10 (IP-10) in response to treatment in Egyptian genotype 4 patients. 159 HCV-genotype 4 patients were included. All patients were treated with Peginterferon alph2a/Ribavirin for 48 wk. The following polymorphisms rs12979…
7
Interleukin (IL)-28B gene polymorphism is closely linked with treatment response to peginterferon plus ribavirin combination therapy for hepatitis C virus genotype 1. However, few studies have reported its effects on therapy for genotype 2. We aimed to examine the effects of IL-28B gene polymorphism on treatment response in hepatitis C virus genotype 2 patients. In a retrospective study of 101 patients infected with either genotype 2a (n = 65) or 2b (n = 36) and treat…
8
To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients. We also explore the behavior of plasma cytokine levels. Retrospective follow-up study. Virologic response to HCV treatment was measured by plasma HCV viral load at different endpoints: rapid virologic response (RVR), early virologic response (E…
9
To evaluate the association of IL28B polymorphisms and severity of liver disease among human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients. We carried out a cross-sectional study on 223 patients. Liver biopsies were evaluated according to Metavir score. IL28B polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) were genotyped using GoldenGate(®) assay. IL28B polymorphisms were in strong linkage disequilibrium, especially the couples rs12980275/rs118812…
10
We focused on determining the most accurate and convenient genotyping methods and most appropriate single nucleotide polymorphism (SNP) among four such polymorphisms associated with interleukin-28B (IL-28B) in order to design tailor-made therapy for patients with chronic hepatitis C virus (HCV) patients. First, five different methods (direct sequencing, high-resolution melting analysis [HRM], hybridization probe [HP], the InvaderPlus assay [Invader], and the TaqMan SNP genotyping assay [TaqMan])…
11
Twenty-five per cent of individuals infected with hepatitis C virus (HCV) are able to clear HCV spontaneously. Differences in host genetics are believed to affect the outcome of HCV infection. We analysed an exonic, a promoter and an intronic single nucleotide polymorphism (SNP) of the interferon-λ3 coding interleukin (IL)-28B gene to study the relationship between IL28B SNPs and outcome of HCV infection. Among 206 HIV-1-infected Europeans with evidence of HCV infection, 47 (23%) individua…
12
  Recent human genome-wide association studies (GWAS) revealed a strong association between IL28B gene variation and the pegylated interferon-α with ribavirin (PEG-IFN-α/RBV) treatment response in chronic hepatitis C patients. Two single nucleotide polymorphisms (SNP), rs8103142 and rs11881222 located in the IL28B gene, were found in significant association with the viral clearance. The present study employed these SNPs to develop a new accessible screening method allowing ide…
13
The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients. We report a genome-wide association study (GWAS) to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population. We found two SNPs near the gene IL28B on chromosome 19 to be strongly associated with NVR (rs12980275, P = 1.93 x 10(-…
Curated Studies0 ▼
These studies were determined to be useful for this variant — check "Unused Studies" further down if curious what didn't make the cut.
No curated studies yet.
Unused Studies0 ▼
No unused studies.